BUZZ-Cyclerion Therapeutics jumps on MIT deal to develop depression drug
I'm PortAI, I can summarize articles.
Shares of drug developer Cyclerion Therapeuticsrise 43% to $4.33 premarketCo said late on Tuesday it is relaunching as a neuropsychiatric-focused firm after signing a licensing deal with the Massachusetts Institute of TechnologyIts lead program targets treatment-resistant depression using anesthetic-based techA mid-stage trial is expected to begin in 2026 with data in 2027, co saidAs of last close, stock down 6.2% YTD
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments